As Per the Report, the North America Non-Invasive Cancer Diagnostics Market Size was valued at USD 45.09 Billion in 2021 and estimated to grow at a CAGR of 6.61%, to reach USD 62.11 billion by 2026 during the forecast period 2021 to 2026.
According to the American Cancer Society, in the U.S., more than 1,660,290 cancer cases were diagnosed in 2013. Growing occurrences of cancer cases are expected to flourish the market growth. Increasing prominence over conventional methods and a growing number of breast cancer cases are leveraging the market demand. Escalating government initiatives for developing healthcare infrastructure in developing countries is mounting the market growth. Non-invasive diagnosis is having quick demand for mounting the growth of the market. Expansion of consciousness in people regarding different types of cancer and the associated treatments is gaining traction towards the market demand.
Enlarging government funds and investments towards research and development activities for the early diagnosis of the disease is gaining market growth. Increasing advancements in technology for cancer detection are augmenting market demand. Growing occurrences of cancer cases, increasing prominence over conventional methods and a growing number of breast cancer cases are some of the significant factors pulling off the market growth.
The cost associated with the diagnosis and treatment procedures regarding cancer is very expensive, which is unaffordable is negatively impacting the market growth. Strict government rules and regulations for the approval of devices and diagnosis is restricting the market demand.
This research report on the North America Non-Invasive Cancer Diagnostics Market has been segmented and sub-segmented into the following categories
Regionally, North America is leading the market with the largest shares in the market. The market size is expected to grow with the highest CAGR during the forecast period 2020-2025. Factors like increasing the patient population suffering from different types of cancer and rising disposable income.
A surge in the introduction of new devices used for diagnosis purposes and growing awareness among the people regarding the symptoms, diagnosis, and treatments are expanding the growth of the non-invasive cancer diagnostics market. Quick advancements in the growth of the technology and invention of the devices are mounting the market demand. Quick product launches, increasing aging population, and rising obesity population are likely to propel the market growth.
The United States Non-Invasive Cancer Diagnostics Market is leading the market with the highest share. The growing number of mergers and acquisitions is escalating market demand. The upsurge in technology advancements by the key players in manufacturing efficient devices and initiatives taken by the government for cancer screening in the early stages are escalating the market growth. The American Cancer Society has made some rules for the detection of cancer, providing different plans at different stages. Women aged between 40 and 44 have to undergo breast cancer screening every year.
The Canada Non-Invasive Cancer Diagnostics Market is next to the U.S in leading the non-invasive cancer diagnostics market. Growing healthcare expenses, rising research studies in the oncology field, and escalation demand for non-invasive cancer diagnosis technologies are progressing the market demand.
Promising Companies dominating the North America Non-Invasive Cancer Diagnostics Market Profiled in the Report are Precision Therapeutics, Laboratory Corporation of America Holdings (LabCorp), BIOVIEW Inc., Affymetrix Inc., AVIVA Biosciences Corporation, A&G Pharmaceutical, Quest Diagnostics Incorporated Cancer Genetics Inc., Digene Corporation, and Gen-Probe Incorporated.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Clinical Chemistry
5.1.4 Molecular Diagnostics
5.1.5 Other Clinical Instruments
5.1.6 Y-o-Y Growth Analysis, By Techniques
5.1.7 Market Attractiveness Analysis, By Techniques
5.1.8 Market Share Analysis, By Techniques
5.2.2 Breast Cancer
5.2.3 Blood cancer
5.2.4 Lung Cancer
5.2.5 Solid tumors
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Techniques
220.127.116.11 By Type
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Techniques
126.96.36.199 By Type
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Techniques
220.127.116.11 By Type
6.2 United States
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AVIVA Biosciences Corporation
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Affymetrix Inc.
8.3 A&G Pharmaceutical
8.4 BIOVIEW Inc.
8.5 Digene Corporation
8.6 Gen-Probe Incorporated
8.7 Laboratory Corporation of America Holdings (LabCorp)
8.8 Precision Therapeutics
8.9 Quest Diagnostics Incorporated
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures